Drugs / QLC1101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06980909 | Jun → Aug 2025 overdue | — | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06403735 | Apr 2024 → May 2026 overdue | colorectal cancer, malignant pancreatic neoplasm, non-small cell lung carcinoma | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06949761 | Jun 2025 → Sep 2026 overdue | neoplasm | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLC1101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06403735 ↗ |
| Action | Inhibit | “inhibit mutant KRAS-dependent signal transduction” NCT06403735 ↗ |
| Modality | Small molecule | “QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D” NCT06403735 ↗ |
| Route | Oral | “administration route of oral administration” NCT06403735 ↗ |
| Target | KRAS | “specifically binding to the KRAS G12D target” NCT06403735 ↗ |